Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Methylprednisolone Sodium Succinate

FDA-approved product (injectable, injection), marketed as A-Methapred, Methylprednisolone, Methylprednisolone Sodium Succinate and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Methylprednisolone Sodium Succinate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Anemia
  • Asthma
  • Atopic eczema
  • Bursitis
  • Crohn's disease
  • Dermatitis
  • Endocrine system disease
  • Frozen shoulder
  • Inflammation
  • Juvenile idiopathic arthritis
  • Leukemia
  • Lymphoma
  • Multiple sclerosis
  • Osteoarthritis
  • Pneumonia
  • and 6 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids, weak (group i); Corticosteroids, combinations for treatment of acne; Glucocorticoids; Corticosteroids for systemic use, combinations
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli30.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis40.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Methylprednisolone Sodium Succinate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Methylprednisolone Sodium Succinate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Oral Care Interventions in PEG-Fed Palliative Care Patients

    NCT07792473 · start 2026-09-07

    Registered record
    Registry ID
    NCT07792473
    Conditions
    Oral Mucosal Integrity; Palliative Care; PEG Feeding
    Interventions
    Ankaferd Hemostat; Benzydamine Hydrochloride 0.15% w/v oromucosal solution; Combined Oral Care Solution
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-09-07
    Completion
    2027-03
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOral Mucosal Integrity; Palliative Care; PEG Feeding
    InterventionAnkaferd Hemostat; Benzydamine Hydrochloride 0.15% w/v oromucosal solution; Combined Oral Care Solution
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis

    NCT07258771 · start 2026-01-16

    Registered record
    Registry ID
    NCT07258771
    Conditions
    Ulcerative Colitis Acute
    Interventions
    Oral Upadacitinib; Intravenous Methylprednisolone; Oral Upadacitinib Placebo; Oral prednisolone Taper; Oral Prednisone - Hospital Dose Steroids
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-01-16
    Completion
    2030-12
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUlcerative Colitis Acute
    InterventionOral Upadacitinib; Intravenous Methylprednisolone; Oral Upadacitinib Placebo; Oral prednisolone Taper +1 more
    PhasePhase 4
    Registry statusRecruiting

  • Adaptive RCT of Corticosteroids for Severe Chlamydia Psittaci Pneumonia in Adults

    NCT07352865 · start 2026-01-15

    Registered record
    Registry ID
    NCT07352865
    Conditions
    Psittacosis
    Interventions
    Saline (0.9%, sterile, for infusion); low dose Methylprednisolone; Moderate dose Methylprednisolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-01-15
    Completion
    2028-11-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsittacosis
    InterventionSaline (0.9%, sterile, for infusion); low dose Methylprednisolone; Moderate dose Methylprednisolone
    PhasePhase 3
    Registry statusNot yet recruiting

  • Neuroendoscopic Hematoma Evacuation Combined With Methylprednisolone Sodium Succinate in the Treatment of Lobar Intracerebral Hemorrhage at the Early Stage.

    NCT06921616 · start 2025-05-01

    Registered record
    Registry ID
    NCT06921616
    Conditions
    Stroke; Intracerebral Hemorrhage Lobar; Methylprednisolone; Surgery
    Interventions
    Simple neuroendoscopic hematoma evacuation; Neuroendoscopic hematoma evacuation combined with sodium methylprednisolone succinate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2025-05-01
    Completion
    2027-01-31
    Enrolment
    396

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStroke; Intracerebral Hemorrhage Lobar; Methylprednisolone; Surgery
    InterventionSimple neuroendoscopic hematoma evacuation; Neuroendoscopic hematoma evacuation combined with sodium methylprednisolone succinate
    PhasePhase 4
    Registry statusNot yet recruiting

  • Autologous Blood Monocyte Vesicles for the Treatment of Sudden Deafness

    NCT06707389 · start 2024-12-25

    Registered record
    Registry ID
    NCT06707389
    Conditions
    Sudden Deafness; Sensorineural Hearing Loss
    Interventions
    autologous blood monocyte vesicles (lower dose); Methylprednisolone; autologous blood monocyte vesicles (higher dose)
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Not yet recruiting
    Start
    2024-12-25
    Completion
    2027-06-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSudden Deafness; Sensorineural Hearing Loss
    Interventionautologous blood monocyte vesicles (lower dose); Methylprednisolone; autologous blood monocyte vesicles (higher dose)
    PhaseEarly phase 1
    Registry statusNot yet recruiting

  • REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE)

    NCT06635720 · start 2024-11-01

    Registered record
    Registry ID
    NCT06635720
    Conditions
    Nephrotic Syndrome in Children; Nephrotic Syndrome, Minimal Change; Nephrotic Syndrome; Nephrotic Syndrome，Idiopathic
    Interventions
    Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2024-11-01
    Completion
    2027-02-28
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNephrotic Syndrome in Children; Nephrotic Syndrome, Minimal Change; Nephrotic Syndrome; Nephrotic Syndrome，Idiopathic
    InterventionPrednisone
    PhasePhase 3
    Registry statusActive not recruiting

  • Transcutaneous Pulsed Radiofrequency and Corticosteroids Injections in Management of Pain in Lateral Epicondylitis

    NCT06710704 · start 2024-04-01

    Registered record
    Registry ID
    NCT06710704
    Conditions
    Transcutaneous; Pulsed Radiofrequency; Corticosteroids Injections; Pain; Lateral Epicondylitis
    Interventions
    Transcutaneous pulsed radiofrequency; Methylprednisolone and mepacaine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2024-04-01
    Completion
    2024-10-24
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTranscutaneous; Pulsed Radiofrequency; Corticosteroids Injections; Pain +1 more
    InterventionTranscutaneous pulsed radiofrequency; Methylprednisolone and mepacaine
    PhaseNot applicable
    Registry statusCompleted

  • Treating Exacerbations of Asthma With Oral Montelukast in Children

    NCT05819541 · start 2023-10-20

    Registered record
    Registry ID
    NCT05819541
    Conditions
    Status Asthmaticus
    Interventions
    Montelukast Oral Granules; Albuterol; Corticosteroid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2023-10-20
    Completion
    2026-03-26
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStatus Asthmaticus
    InterventionMontelukast Oral Granules; Albuterol; Corticosteroid
    PhasePhase 2
    Registry statusCompleted

  • A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

    NCT05800366 · start 2023-04-06

    Registered record
    Registry ID
    NCT05800366
    Conditions
    Lymphoma; Lymphoma, Large B-Cell, Diffuse
    Interventions
    Glofitamab; Polatuzumab; Rituximab; Doxorubicin Hydrochloride; Cyclophosphamide; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-04-06
    Completion
    2029-09-15
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma; Lymphoma, Large B-Cell, Diffuse
    InterventionGlofitamab; Polatuzumab; Rituximab; Doxorubicin Hydrochloride +2 more
    PhasePhase 2
    Registry statusRecruiting

  • Combination of Fluoroscopy and Ultrasonography Guidance in Sacroiliac Joint Injections. A Randomised Controlled Trial

    NCT05944861 · start 2023-02-15

    Registered record
    Registry ID
    NCT05944861
    Conditions
    Sacroiliac Joint Somatic Dysfunction; Sacroiliac Joint Pain
    Interventions
    Combined ultrasonography and flouroscopy guided injeciton; Flouroscopy guided injection
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-02-15
    Completion
    2024-02-15
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSacroiliac Joint Somatic Dysfunction; Sacroiliac Joint Pain
    InterventionCombined ultrasonography and flouroscopy guided injeciton; Flouroscopy guided injection
    PhaseNot applicable
    Registry statusCompleted

  • Functional Strength Training and Neuromuscular Electrical Stimulation in Severe Acute Exacerbations of COPD

    NCT05480566 · start 2022-06-01

    Registered record
    Registry ID
    NCT05480566
    Conditions
    Acute Exacerbation of Chronic Obstructive Pulmonary Disease; Acute Exacerbation of COPD
    Interventions
    Functional strength training; NMES; Daily medical treatment (e.g., oxygen, medrol, duovent, azitromycine); Routine physiotherapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2022-06-01
    Completion
    2023-12-01
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Exacerbation of Chronic Obstructive Pulmonary Disease; Acute Exacerbation of COPD
    InterventionFunctional strength training; NMES; Daily medical treatment (e.g., oxygen, medrol, duovent, azitromycine); Routine physiotherapy
    PhaseNot applicable
    Registry statusTerminated

  • Comparison of Different Volumes Spread of Erector Spinae Block in Post Mastectomy Pain Syndrome Management

    NCT05192278 · start 2021-12-12

    Registered record
    Registry ID
    NCT05192278
    Conditions
    Breast Cancer
    Interventions
    erector spinae block
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-12-12
    Completion
    2022-09-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionerector spinae block
    PhasePhase 2
    Registry statusUnknown

  • Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard Therapy

    NCT04376528 · start 2021-06-16

    Registered record
    Registry ID
    NCT04376528
    Conditions
    Hepatitis, Autoimmune; Primary Biliary Cholangitis; Immunosuppression
    Interventions
    Cyclosporin A; Mycophenolate Mofetil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-06-16
    Completion
    2021-12-30
    Enrolment
    89

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis, Autoimmune; Primary Biliary Cholangitis; Immunosuppression
    InterventionCyclosporin A; Mycophenolate Mofetil
    PhasePhase 4
    Registry statusUnknown

  • MIS-C Comparative Effectiveness Study

    NCT04898231 · start 2020-12-22

    Registered record
    Registry ID
    NCT04898231
    Conditions
    Multisystem Inflammatory Syndrome-Children
    Interventions
    Infliximab; Anakinra; Methylprednisolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2020-12-22
    Completion
    2024-04-25
    Enrolment
    73

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultisystem Inflammatory Syndrome-Children
    InterventionInfliximab; Anakinra; Methylprednisolone
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

    NCT04519476 · start 2020-11-01

    Registered record
    Registry ID
    NCT04519476
    Conditions
    Refractory Multiple Myeloma
    Interventions
    Selinexor; Lenalidomide; Methylprednisolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2020-11-01
    Completion
    2023-12-29
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRefractory Multiple Myeloma
    InterventionSelinexor; Lenalidomide; Methylprednisolone
    PhasePhase 1
    Registry statusUnknown